Table 4. Biologic outcome during a... | American Society of Hematology

Table 4.

Biologic outcome during a 6-year follow-up of 32 patients

	Hydroxyurea therapy
	Before	1 year	2 years	3 years	4 years	5 years	6 years
Hemoglobin level, g/dL	8.2 (6.7-10)	8.7 (6.7-12)†	9.0 (6.2-12)*	8.7 (6.8-13)†	8.6 (6.6-14)†	8.8 (6.7-14)†	8.8 (6.9-11)†
HbF level, g/dL	0.3 (0.01-0.8)	1.4 (0.01-5.1)*	1.4 (0.12-4.3)*	1.4 (0.17-3.8)*	1.3 (0.16-3.2)*	1.0 (0.10-2.8)*	1.1 (0.08-2.5)*
MCV, fL	83 (68-113)	93 (69-117)*	93 (75-118)*	91 (70-118)	93 (74-119)	91 (70-121)	92 (67-120)
ANC, × 10⁹/L	5.2 (2.8-9.3)	3.4 (1.4-6.6)*	4.5 (1.3-12)	4.2 (2.2-11)	4.3 (0.8-10)	4.8 (1.5-11)	4.6 (2.0-15)

	Hydroxyurea therapy
	Before	1 year	2 years	3 years	4 years	5 years	6 years
Hemoglobin level, g/dL	8.2 (6.7-10)	8.7 (6.7-12)†	9.0 (6.2-12)*	8.7 (6.8-13)†	8.6 (6.6-14)†	8.8 (6.7-14)†	8.8 (6.9-11)†
HbF level, g/dL	0.3 (0.01-0.8)	1.4 (0.01-5.1)*	1.4 (0.12-4.3)*	1.4 (0.17-3.8)*	1.3 (0.16-3.2)*	1.0 (0.10-2.8)*	1.1 (0.08-2.5)*
MCV, fL	83 (68-113)	93 (69-117)*	93 (75-118)*	91 (70-118)	93 (74-119)	91 (70-121)	92 (67-120)
ANC, × 10⁹/L	5.2 (2.8-9.3)	3.4 (1.4-6.6)*	4.5 (1.3-12)	4.2 (2.2-11)	4.3 (0.8-10)	4.8 (1.5-11)	4.6 (2.0-15)

No statistically significant change at 4, 5, and 6 years respectively for all parameters when compared with 3 years.

Results are expressed as median (range).

Statistically significant change from baseline, defined by P < .001.

Statistically significant change from baseline, defined by P < .05.